<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03889028</url>
  </required_header>
  <id_info>
    <org_study_id>NAV-CMV-2019</org_study_id>
    <nct_id>NCT03889028</nct_id>
  </id_info>
  <brief_title>Pre-engraftment Cytomegalovirus DNAemia</brief_title>
  <official_title>Pre-engraftment Cytomegalovirus DNAemia in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Incidence, Risk Factors and Clinical Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación para la Investigación del Hospital Clínico de Valencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación para la Investigación del Hospital Clínico de Valencia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cytomegalovirus (CMV) DNAemia occurs frequently in allogeneic hematopoietic stem cell&#xD;
      transplant (allo-HSCT) recipients.Both high-level and persistent virus DNAemia are known risk&#xD;
      factors for CMV end-organ disease and perhaps non-relapse mortality. CMV DNAemia is usually&#xD;
      documented after engraftment, but it may occur before. The virological features and clinical&#xD;
      consequences of these latter early-onset episodes remain largely unexplored. The U.S. Food&#xD;
      and Drug Administration (FDA) has recently approved letermovir for prophylaxis of CMV&#xD;
      infection and disease in adult CMV-seropositive allo-HSCT recipients (PREVYMIS™, Merck &amp; Co.,&#xD;
      New Jersey, USA). In accordance with the design of the phase III, double-blind trial the drug&#xD;
      may be administered as early as the day of transplant and no later than 28 days&#xD;
      post-transplant. Nevertheless, the timing of drug inception should be contingent on the&#xD;
      clinical impact of very early episodes of CMV DNAemia. In a recent work from our group&#xD;
      (single-center study) we found that a total 38 out of the 197 patients in our series&#xD;
      developed CMV DNAemia before engraftment (cumulative incidence (CI), 19%; 95% CI, 10-30.3%).&#xD;
      Nine episodes of CMV DNAemia were detected prior to the time of donor progenitor cell&#xD;
      infusion. A greater number of post-engraftment episodes required preemptive antiviral therapy&#xD;
      compared with pre-engraftment episodes (62.5% vs 44.7%; P=0.05). The cellular content of the&#xD;
      donor progenitor cell infusion and transplant characteristics of patients did not differ&#xD;
      between patients with pre- or post-engraftment CMV DNAemia. The cumulative incidence of&#xD;
      overall mortality by days 100 and 365, aGvHD by day 100 and relapse by day 365 were not&#xD;
      significantly different between patients with pre-engraftment or post-engraftment CMV&#xD;
      DNAemia. Our study was limited by the retrospective and single-center design and the scarce&#xD;
      number of pre-engraftment CMV DNAemia episodes included; therefore, the results may not be&#xD;
      extrapolated to other transplantation centers or patient cohorts. Further retrospective and&#xD;
      prospective studies are thus required to validate the data presented herein.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Episodes of CMV DNAemia developing prior to engraftment (pre-CMV DNAemia), which usually&#xD;
      occur between the third and fourth week after allo-HSCT, may conceivably have a different&#xD;
      course from episodes emerging after engraftment once patients have begun to expand&#xD;
      donor-derived T cells (post-CMV DNAemia). Thus, whether the precise timing of Letermovir&#xD;
      treatment initiation should matter will ultimately depend on the impact of CMV DNAemia&#xD;
      episodes developing prior to engraftment on clinical outcomes. There is limited information&#xD;
      available on this topic. Here, we conducted a retrospective multicenter, non-interventional&#xD;
      study to further address this issue.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2, 2019</start_date>
  <completion_date type="Actual">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">September 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Engraftment (Days) Stratified by CMV DNaemia Occurring Before or After Neutrophil's Engraftment</measure>
    <time_frame>30 days</time_frame>
    <description>absolute neutrophil count ≥500/mm3 on 3 consecutive days,, the first of which being time of engraftment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>total number of deaths from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>total number of deaths without relapse or underlying disease progression</description>
  </secondary_outcome>
  <enrollment type="Actual">878</enrollment>
  <condition>CMV DNAemia Pre-engraftment</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive allo-HSCT recipients at risk of CMV infection allografted from 1st January&#xD;
        2010 until 31th December 2017 in Spanish transplant centers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recipients &gt;18 years old&#xD;
&#xD;
          -  CMV seropositive recipients and/or donors&#xD;
&#xD;
          -  First allo-HSCT (T cell replete)&#xD;
&#xD;
          -  CMV DNA load monitoring by real-time PCR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recipients &lt; 18 years&#xD;
&#xD;
          -  CMV seronegative donors and recipients.&#xD;
&#xD;
          -  No CMV DNA load monitoring&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical University Hospital of Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 22, 2019</study_first_submitted>
  <study_first_submitted_qc>March 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2019</study_first_posted>
  <results_first_submitted>October 5, 2020</results_first_submitted>
  <results_first_submitted_qc>November 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2020</results_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación para la Investigación del Hospital Clínico de Valencia</investigator_affiliation>
    <investigator_full_name>David Navarro</investigator_full_name>
    <investigator_title>David Navarro, MD, PhD</investigator_title>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT03889028/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult patients undergoing T-cell replete allo-HSCT at 20 different centers in Spain from September 2014 to December 2015 (Registry of the Working group on Infectious and Non-Infectious Complications of the GETH-Spanish Hematopoietic Transplantation and Cell Therapy Group-). A total of 218 adult patients who received an unmanipulated allo-HSCT at the Clinical University Hospital of Valencia from March 2010 to May 2019 (excluding patients recruited in the GETH registry) were also included</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pre-CMV DNAemia</title>
          <description>Patients who developed CMV DNAemia prior to engraftment</description>
        </group>
        <group group_id="P2">
          <title>Post-CMV DNAemia</title>
          <description>Patients with CMV DNAemia detected after neutrophil's engraftment</description>
        </group>
        <group group_id="P3">
          <title>No CMV DNAemia</title>
          <description>Patients without CMV DNAemia throughout the study period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="422"/>
                <participants group_id="P3" count="312"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="422"/>
                <participants group_id="P3" count="312"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pre-CMV DNAemia</title>
          <description>Patients with CMV DNAemia detected prior neutrophil's engraftment</description>
        </group>
        <group group_id="B2">
          <title>Post-CMV DNAemia</title>
          <description>Patients with CMV DNAemia detected after neutrophil's engraftment</description>
        </group>
        <group group_id="B3">
          <title>No CMV</title>
          <description>Patients without CMV DNAemia</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="144"/>
            <count group_id="B2" value="422"/>
            <count group_id="B3" value="312"/>
            <count group_id="B4" value="878"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="370"/>
                    <measurement group_id="B3" value="275"/>
                    <measurement group_id="B4" value="779"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="135"/>
                    <measurement group_id="B4" value="366"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="248"/>
                    <measurement group_id="B3" value="177"/>
                    <measurement group_id="B4" value="512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="422"/>
                    <measurement group_id="B3" value="312"/>
                    <measurement group_id="B4" value="878"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Engraftment (Days) Stratified by CMV DNaemia Occurring Before or After Neutrophil's Engraftment</title>
        <description>absolute neutrophil count ≥500/mm3 on 3 consecutive days,, the first of which being time of engraftment.</description>
        <time_frame>30 days</time_frame>
        <population>Patients with CMV DNAemia</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-CMV DNAemia</title>
            <description>episodes of CMV DNAemia that were detected prior to engraftment</description>
          </group>
          <group group_id="O2">
            <title>Post-CMV DNAemia</title>
            <description>episodes of CMV DNAemia that were detected after engraftment</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Engraftment (Days) Stratified by CMV DNaemia Occurring Before or After Neutrophil's Engraftment</title>
          <description>absolute neutrophil count ≥500/mm3 on 3 consecutive days,, the first of which being time of engraftment.</description>
          <population>Patients with CMV DNAemia</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="422"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="8" upper_limit="42"/>
                    <measurement group_id="O2" value="19" lower_limit="5" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Mortality</title>
        <description>total number of deaths from any cause</description>
        <time_frame>1 year</time_frame>
        <population>Patients with CMV DNAemia detected prior or after neutrophil's engraftment</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-CMV DNAemia</title>
            <description>episodes of CMV DNAemia that were detected prior to engraftment</description>
          </group>
          <group group_id="O2">
            <title>Post-CMV DNAemia</title>
            <description>episodes of CMV DNAemia that were detected after engraftment</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mortality</title>
          <description>total number of deaths from any cause</description>
          <population>Patients with CMV DNAemia detected prior or after neutrophil's engraftment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="422"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-relapse Mortality</title>
        <description>total number of deaths without relapse or underlying disease progression</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-CMV DNAemia</title>
            <description>episodes of CMV DNAemia that were detected prior to engraftment</description>
          </group>
          <group group_id="O2">
            <title>Post-CMV DNAemia</title>
            <description>episodes of CMV DNAemia that were detected after engraftment</description>
          </group>
        </group_list>
        <measure>
          <title>Non-relapse Mortality</title>
          <description>total number of deaths without relapse or underlying disease progression</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="422"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>death from any cause</desc>
      <group_list>
        <group group_id="E1">
          <title>Pre-CMV DNAemia</title>
          <description>Patients with CMV DNAemia detected prior neutrophil's engraftment</description>
        </group>
        <group group_id="E2">
          <title>Post-CMV DNAemia</title>
          <description>Patients with CMV DNAemia detected after neutrophil's engraftment</description>
        </group>
        <group group_id="E3">
          <title>No CMV DNAemia</title>
          <description>Patients without CMV DNAemia</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Navarro</name_or_title>
      <organization>Clinical University Hospital of Valencia</organization>
      <phone>+34961973500</phone>
      <email>david.navarro@uv.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

